Effient to reduce heart attack risk in angioplasty patients

by Anil Kumar



The U.S. Food and Drug Administration has approved the Eli Lilly's blood-thinning drug Effient tablets (prasugrel) to reduce the risk of blood clots from forming in patients who undergo angioplasty, a common procedure to unblock a clogged coronary artery.

During an angioplasty, a balloon is used to open the artery that has been narrowed by atherosclerotic plaque. Often, a tiny wire mesh scaffold (stent) is inserted into the blood vessel to help keep the artery open after the procedure.

Platelets in the blood can clump around the procedure site, causing clots that can lead to heart attack, and stroke.

Effient was studied in a 13,608-patient trial comparing it to the blood-thinning drug, Plavix (clopidogrel), in patients with a threatened heart attack or an actual heart attack who were about to undergo angioplasty.

The fraction of patients who had subsequent non-fatal heart attacks was reduced from 9.1 percent in patients who received Plavix to 7.0 percent in patients who received Effient.While the numbers of deaths and strokes were similar with both drugs, patients with a history of stroke were more likely to have another stroke while taking Effient. In addition, there was a greater risk of significant, sometimes fatal bleeding seen in patients who took Effient.

"Effient offers physicians an alternative treatment for preventing dangerous blood clots from forming and causing a heart attack or stroke during or after an angioplasty procedure," said John Jenkins, M.D., director of the Office of New Drugs, in the FDA's Center for Drug Evaluation and Research."Physicians must carefully weigh the potential benefits and risks of Effient as they decide which patients should receive the drug."

The drug's labeling will include a boxed warning alerting physicians that the drug can cause significant, sometimes fatal, bleeding. The drug should not be used in patients with active pathological bleeding, a history of mini-strokes (transient ischemic attacks) or stroke, or urgent need for surgery, including coronary artery bypass graft surgery.

Effient is manufactured by Eli Lilly and Company of Indianapolis, in partnership with Tokyo-based Daiichi Sankyo Ltd.


(Anil Kumar -- sub-editor compiled and published Effient to reduce heart attack risk in angioplasty patients at HealthNewsTrack on July 11, 2009 sourced from U.S. Food and Drug Administration - http://www.fda.gov/)

Heart Attack - recent articles and current news stories:

- Anticoagulant Dabigatran linked to heart attack or MI
- Bariatric surgery reduces heart attack and stroke in obese
- Stent design may put patients at risk of heart attack
- Yearly visit to dentist can reduce heart attack risk
- Door-to-balloon time is 90 min in 91% of heart attack patients in US

Heart Attack article/news source:

Read more health articles from U.S. Food and Drug Administration and health articles from USA.

Heart Attack - search related terms:

Angioplasty, Balloon, Blood thinning drug, Coronary artery, Effient, Heart attack, Heart attack, Plavix, Prasugrel, Stent, Stroke,
Heart Attack books,

Searched keywords: effient (24), prasugrel (8),

Subscribe to Health News by Email

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
3.3